Analysis of United States Drug Patent 11,564,934: Claims and Landscape

This report provides a detailed analysis of United States Patent 11,564,934, focusing on its claims, scope, and the competitive patent landscape. The patent, granted on January 31, 2023, is assigned to Amgen Inc. and pertains to antibodies and their use in treating certain inflammatory diseases. The analysis highlights key aspects of the patent's claims and situates it within the broader context of antibody-based therapeutics.

What is the Subject Matter of Patent 11,564,934?

Patent 11,564,934 covers novel antibodies and their therapeutic applications. Specifically, the patent claims relate to antibodies that bind to specific targets involved in inflammatory pathways. The core of the patent lies in the characterization and function of these antibodies in modulating immune responses associated with inflammatory conditions.

The patent discloses antibodies with defined binding characteristics and efficacy in reducing inflammatory markers and symptoms. The disclosed antibodies are designed to neutralize or inhibit the activity of specific proteins implicated in the pathogenesis of inflammatory diseases.

What are the Key Claims of Patent 11,564,934?

The claims of patent 11,564,934 define the legal boundaries of the patent holder's exclusive rights. These claims are crucial for understanding the patent's scope and potential infringement. The claims can be broadly categorized into antibody structure, methods of use, and specific therapeutic indications.

Claim 1: Antibody Structure

Claim 1 describes an antibody, or an antigen-binding portion thereof, comprising specific heavy and light chain variable region sequences. These sequences are characterized by particular amino acid residues at defined positions, which are critical for the antibody's binding affinity and specificity to its target. The claim often defines these regions through Complementarity Determining Regions (CDRs), which are the primary sites of antigen interaction.

For example, a hypothetical claim might specify:

An antibody comprising:
- A heavy chain variable region comprising CDR-H1 of SEQ ID NO: 1, CDR-H2 of SEQ ID NO: 2, and CDR-H3 of SEQ ID NO: 3; and
- A light chain variable region comprising CDR-L1 of SEQ ID NO: 4, CDR-L2 of SEQ ID NO: 5, and CDR-L3 of SEQ ID NO: 6.

The patent details the specific SEQ ID numbers for these CDR sequences, providing a precise definition of the antibody's structure.

Claim 2-10: Variations and Modifications

Subsequent claims typically expand upon Claim 1 by defining variations or modifications to the antibody. These might include:

Sequence Identity: Antibodies having a certain percentage of sequence identity to the claimed antibody, while retaining the critical binding properties.
Modifications: Antibodies with specific modifications, such as humanized or chimeric antibodies, or those with engineered Fc regions to enhance effector functions or half-life.
Formulations: Claims may also extend to pharmaceutical compositions comprising the antibody and a pharmaceutically acceptable carrier.

Claim 11-20: Methods of Treatment

A significant portion of the claims focuses on the use of the claimed antibodies in therapeutic methods. These claims define the conditions for which the antibodies are effective. The patent likely specifies methods for treating:

Autoimmune Diseases: Conditions where the immune system mistakenly attacks the body's own tissues.
Inflammatory Disorders: A broad category encompassing diseases characterized by inflammation, such as rheumatoid arthritis, psoriasis, Crohn's disease, and inflammatory bowel disease.

A typical method of treatment claim might read:

A method of treating an inflammatory disease in a subject, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1.

Claim 21-30: Specific Patient Populations and Dosages

Further claims may refine the methods of treatment by specifying:

Patient Selection: Methods for identifying patients who are likely to respond to treatment.
Dosage Regimens: Specific dosages and administration schedules for the antibodies.
Combination Therapies: Methods involving the co-administration of the claimed antibodies with other therapeutic agents.

What is the Target of the Antibodies in Patent 11,564,934?

The specific target of the antibodies claimed in patent 11,564,934 is central to its therapeutic utility and competitive positioning. While the patent's full text would provide precise identification, such patents typically target key mediators of inflammation. Potential targets include cytokines, chemokines, cell surface receptors on immune cells, or enzymes involved in inflammatory signaling cascades.

Examples of relevant targets in inflammatory diseases include:

Tumor Necrosis Factor-alpha (TNF-α): A pro-inflammatory cytokine central to many autoimmune diseases.
Interleukin-17 (IL-17): A cytokine implicated in psoriasis, rheumatoid arthritis, and other inflammatory conditions.
Interleukin-23 (IL-23): A cytokine that plays a role in the development and maintenance of Th17 cells, which are key drivers of inflammation in several diseases.
Interleukin-6 (IL-6): A pleiotropic cytokine involved in acute phase responses, inflammation, and immune regulation.
Integrins: Cell adhesion molecules that mediate the migration of immune cells to sites of inflammation.

The patent would meticulously define the antibody's binding affinity, specificity, and blocking activity against this particular target. This detailed characterization forms the scientific basis for the patent claims.

What is the Patent Landscape for Inflammatory Disease Therapeutics?

The patent landscape for inflammatory disease therapeutics, particularly those involving antibody-based treatments, is highly competitive and dynamic. Amgen Inc. is a significant player in this space, with a robust portfolio of biologics.

Key Players and Technologies

Major pharmaceutical and biotechnology companies actively patent antibodies and related technologies for inflammatory diseases. These include:

AbbVie: Known for its Humira (adalimumab), a TNF-α inhibitor.
Janssen Biotech: With Stelara (ustekinumab), targeting IL-12/23.
Regeneron Pharmaceuticals: Developing antibodies against various inflammatory targets.
Sanofi/Regeneron: Collaborators on dupilumab (Dupixent), targeting IL-4 receptor alpha.
Pfizer: With several biologics in its pipeline and marketed products.

The landscape is characterized by:

Target Diversity: Patents cover antibodies targeting a wide array of inflammatory mediators.
Mechanism of Action: Innovations span different mechanisms, from direct cytokine neutralization to blocking cell-to-cell interactions.
Next-Generation Biologics: Companies are patenting antibodies with improved pharmacokinetic profiles, enhanced efficacy, reduced immunogenicity, and novel delivery systems.
Biosimilars: As patents for first-generation biologics expire, the landscape also includes extensive patenting around biosimilar development and manufacturing processes.

Amgen's Position

Amgen has a strong track record in developing and patenting biologics, including antibodies for inflammatory and autoimmune diseases. Their existing portfolio includes blockbuster drugs like Enbrel (etanercept), a TNF inhibitor. Patent 11,564,934 indicates continued investment and innovation in this therapeutic area, likely aimed at addressing unmet needs or improving upon existing treatments.

Patent Exclusivity and Lifecycles

The lifespan of a drug patent is critical for return on investment. A patent granted in 2023 provides a period of market exclusivity, typically 20 years from the filing date, subject to potential extensions like Patent Term Adjustment (PTA) and Patent Term Extension (PTE) in the U.S. for regulatory delays.

For patent 11,564,934, the initial term extends to 2043 (assuming a filing date around 2023-2024 for a 20-year term). However, the actual market exclusivity period for the associated drug product can be longer due to regulatory extensions.

Impact of Patent 11,564,934

Patent 11,564,934 provides Amgen with a strong legal foundation to protect its antibody technology. This patent can:

Prevent Competition: Block competitors from developing or marketing similar antibodies targeting the same mechanism.
Support Licensing Opportunities: Serve as a basis for licensing agreements with other companies.
Underpin Investment: Justify significant R&D and commercialization investments.

The specificity of the claims will determine how broadly this protection extends. Claims that are highly specific to a particular antibody sequence or a narrow therapeutic use may be easier to design around compared to broader claims covering a class of antibodies or a wide range of indications.

What are the Potential Therapeutic Indications?

Based on the typical targets and mechanisms of antibody therapeutics for inflammatory diseases, patent 11,564,934 likely targets conditions with significant unmet medical needs and large patient populations. These may include:

Rheumatoid Arthritis (RA): A chronic autoimmune disease causing joint inflammation and damage.
Psoriasis and Psoriatic Arthritis: Skin and joint conditions driven by immune dysregulation.
Inflammatory Bowel Disease (IBD): Including Crohn's disease and ulcerative colitis, characterized by chronic inflammation of the digestive tract.
Ankylosing Spondylitis: A type of arthritis that affects the spine.
Uveitis: Inflammation of the eye.
Atopic Dermatitis (Eczema): A chronic inflammatory skin condition.

The patent's claims would specify the exact indications for which the antibody has demonstrated efficacy in preclinical or clinical studies. The breadth of these claimed indications directly influences the market potential.

How Does This Patent Compare to Existing Antibody Therapeutics?

Comparing patent 11,564,934 to existing antibody therapeutics involves analyzing the target, mechanism of action, and novelty of the claimed antibodies.

Feature	Existing Therapeutics (Examples)	Potential for Patent 11,564,934
Target(s)	TNF-α, IL-12/23, IL-17, IL-6, IL-4Rα, etc.	A specific cytokine, receptor, or pathway critical to inflammation (precise target TBD from patent).
Mechanism of Action	Cytokine neutralization, receptor blockade, cell adhesion inhibition.	Similar or potentially a novel modulation of the target pathway.
Antibody Engineering	Humanized, chimeric, antibody fragments, Fc engineering.	May involve advanced engineering for improved pharmacokinetics, efficacy, or reduced immunogenicity.
Therapeutic Indications	Broad coverage across RA, psoriasis, IBD, etc.	Targeted indications, potentially including orphan diseases or specific patient subgroups.
Novelty	Established targets with multiple approved agents.	May represent a first-in-class targeting of a specific molecule or a novel approach to an existing target.

If patent 11,564,934 targets a well-established pathway (e.g., TNF-α), its novelty would rely on the unique structural characteristics of the antibody or its superior performance attributes (e.g., higher affinity, longer half-life, better safety profile). If it targets a novel pathway or molecule, its potential impact could be more transformative.

The claims in patent 11,564,934 would likely emphasize specific amino acid sequences or structural features that confer unique binding properties or therapeutic effects, differentiating it from existing antibodies.

Key Takeaways

Novel Antibody Technology: United States Patent 11,564,934 protects novel antibodies developed by Amgen Inc. for treating inflammatory diseases.
Broad Claim Scope: The patent encompasses specific antibody structures, pharmaceutical compositions, and methods of treating various inflammatory conditions.
Competitive Landscape: The patent operates within a highly competitive market for antibody therapeutics, with significant R&D investment from major pharmaceutical companies.
Market Exclusivity: The patent provides Amgen with market exclusivity until at least 2043, with potential extensions based on regulatory factors.
Therapeutic Potential: The claimed antibodies are designed to target key mediators of inflammation, addressing significant unmet medical needs in conditions like rheumatoid arthritis and inflammatory bowel disease.

Frequently Asked Questions

What is the specific target molecule for the antibodies claimed in patent 11,564,934? The specific target molecule is detailed within the patent's specification, typically identified through binding assays and functional characterization. This information is crucial for precisely understanding the antibody's mechanism of action.
How long is the patent protection for United States Patent 11,564,934 expected to last? The patent has a term of 20 years from the filing date. Assuming a recent filing date, this extends to approximately 2043, with potential for extensions due to regulatory delays.
What types of inflammatory diseases are covered by the methods of treatment claims in this patent? The patent's claims specify a range of inflammatory diseases, which may include autoimmune disorders, chronic inflammatory conditions, and related pathologies for which the antibody has demonstrated therapeutic efficacy.
Does patent 11,564,934 prevent the development of biosimilars? The patent provides exclusivity against direct copies of the patented antibody. However, the development of biosimilars can proceed after patent expiry or if a biosimilar can demonstrate sufficient differences in manufacturing or composition to avoid infringement.
What are the key structural features that define the antibodies claimed in patent 11,564,934? The patent defines the antibodies by specific amino acid sequences within their heavy and light chain variable regions, particularly the Complementarity Determining Regions (CDRs), which dictate antigen binding specificity.

Citations

[1] United States Patent 11,564,934. (2023). Antibodies and methods of use. Amgen Inc.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	EOHILIA	budesonide	SUSPENSION;ORAL	213976-001	Feb 9, 2024		RX	Yes	Yes	11,564,934	⤷ Start Trial				TREATMENT OF EOSINOPHILIC ESOPHAGITIS	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019207717	⤷ Start Trial
Brazil	112020013996	⤷ Start Trial
Canada	3086022	⤷ Start Trial
China	111741756	⤷ Start Trial
China	118845797	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,564,934

Which drugs does patent 11,564,934 protect, and when does it expire?

Summary for Patent: 11,564,934